Navigation Links
Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS)
Date:5/19/2009

>

There was no difference between pirfenidone and placebo in the percentage of patients who experienced a serious adverse event (SAE). An SAE was reported by 35% and 33% of pirfenidone and placebo groups, respectively, in CAPACITY 2 and by 31% and 30%, respectively, in CAPACITY 1. While there was a slightly higher incidence of Grade 3 adverse events in the pirfenidone groups in both studies, there was no difference in overall Grade 4 adverse events between pirfenidone and placebo.

The pattern of adverse events was in general comparable to that observed in previous clinical studies of pirfenidone. The most common adverse events in the pirfenidone group as compared to placebo were nausea (35% vs. 18% in CAPACITY 2 and 38% vs. 16% in CAPACITY 1), rash (31% vs. 10% and 34% vs. 13%), fatigue (28% vs. 21% and 33% vs. 20%), diarrhea (25% vs. 17% and 33% vs. 21%), dyspepsia (17% vs. 9% and 21% vs. 6%), and dizziness (19% vs. 10% and 18% vs. 10%). Rash was generally mild to moderate in both studies; only 2 patients (1 in each CAPACITY study) receiving pirfenidone experienced a severe rash.

ADDITIONAL SAFETY RESULTS REPORTED

The ATS presentation reported new safety data from the CAPACITY studies pertaining to the incidence and cause of deaths, treatment discontinuations due to adverse events and laboratory tests.

Incidence and Cause of Deaths

Analysis of the incidence and cause of death revealed that fewer patients in the pirfenidone 2403 mg group compared with placebo died during the treatment period, defined as the time from the first dose until 28 days after the last dose of study treatment. In CAPACITY 1, 5.3% of patients in the pirfenidone group died during the treatment period, compared with 8.7% in the placebo group. In CAPACITY 2, 5.7% of patients in the pirfenidone group died during the treatment period, compared with 8.0% in the placebo group.

The incidence
'/>"/>

SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Shire Announces Study Results of the Effects of INTUNIV(TM) (Guanfacine) Extended Release on Secondary Measures in Children with ADHD and Oppositional Symptoms
2. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
3. BioVex to Report Phase I/II Clinical Trial Results for the Front Line Treatment of Head and Neck Cancer With OncoVEX GM-CSF at the 2009 American Society of Clinical Oncology Meeting
4. TYRX Presents Early Clinical Results from AIGISRX(TM) Antibacterial Envelope Retrospective Registry
5. Metabolic Solutions Development Company Announces Preliminary Results from Phase IIa Clinical Trial
6. AlphaVax Announces Promising Results in Melanoma Studies
7. Ongoing Landmark ROADMAP Study Demonstrates Significant Improvement in Blood Pressure Control at One Year, According to Blinded Results
8. BioCryst Provides Peramivir Update and Reports First Quarter 2009 Financial Results
9. Bionovo Announces First Quarter 2009 Highlights and Financial Results
10. Alexza Reports 2009 First Quarter Financial Results and Updates Clinical Pipeline Status
11. ADVENTRX Announces Results From ANX-514 Bioequivalence Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... Texas , Aug. 21, 2014  eRelevance ... services company, announced today that it has completed ... (EMR) solution for Plastic Surgery and Dermatology practices. ... even more value to healthcare practices using Nextech," ... of eRelevance Corporation. "Using information from the EMR ...
(Date:8/21/2014)... , Aug. 21, 2014 The spinal column is ... human body. Signals carried to and from the brain through ... and nervous system. Injury or ailment here can be life ... a loss of control over their body. Though back injury ... person,s life, there are more options available to make things ...
(Date:8/21/2014)... Aug. 21, 2014  Publicis Groupe customer engagement ... Managing Partner and Healthcare Industry Group Leader, has been ... recognizes the most inspiring people in the life-sciences industry. ... research and development, marketing, technology, creativity, strategy and medicine. ... as a partner in its leading Rosetta Consulting practice. ...
Breaking Medicine Technology:eRelevance Corporation Integrates with Nextech Electronic Medical Records 2Don't Live in Pain: Four Life Improving Benefits of Back Surgery 2Shannon Hartley Shines in PharmaVOICE 100 2
... Cell Therapeutics, Inc. ("CTI") (NASDAQ and MTA: ... of the peer reviewed journal, Leukemia & ... of a phase I/II clinical trial evaluating the ... in treating patients with aggressive non-Hodgkin,s lymphoma ("NHL") ...
... BASKING RIDGE, N.J., April 3, 2011 Regado Biosciences, ... antithrombotic aptamers with active control agents, announced today the ... of the company,s lead product, the anticoagulation system REG1, ... Cardiology 2011 60th Annual Scientific Session & Expo in ...
Cached Medicine Technology:Substitution of Pixantrone for Doxorubicin in CHOP Chemotherapy Regimen Produces High Rates of Complete Remissions and Long-Term Disease Free Survival in Patients with Relapsed/Refractory Aggressive NHL Who Previously Failed Frontline CHOP Therapy 2Substitution of Pixantrone for Doxorubicin in CHOP Chemotherapy Regimen Produces High Rates of Complete Remissions and Long-Term Disease Free Survival in Patients with Relapsed/Refractory Aggressive NHL Who Previously Failed Frontline CHOP Therapy 3Substitution of Pixantrone for Doxorubicin in CHOP Chemotherapy Regimen Produces High Rates of Complete Remissions and Long-Term Disease Free Survival in Patients with Relapsed/Refractory Aggressive NHL Who Previously Failed Frontline CHOP Therapy 4Substitution of Pixantrone for Doxorubicin in CHOP Chemotherapy Regimen Produces High Rates of Complete Remissions and Long-Term Disease Free Survival in Patients with Relapsed/Refractory Aggressive NHL Who Previously Failed Frontline CHOP Therapy 5Substitution of Pixantrone for Doxorubicin in CHOP Chemotherapy Regimen Produces High Rates of Complete Remissions and Long-Term Disease Free Survival in Patients with Relapsed/Refractory Aggressive NHL Who Previously Failed Frontline CHOP Therapy 6Regado Biosciences, Inc. Presents Results of the RADAR Phase 2b Clinical Trial of its REG1 Anticoagulation System 2Regado Biosciences, Inc. Presents Results of the RADAR Phase 2b Clinical Trial of its REG1 Anticoagulation System 3Regado Biosciences, Inc. Presents Results of the RADAR Phase 2b Clinical Trial of its REG1 Anticoagulation System 4Regado Biosciences, Inc. Presents Results of the RADAR Phase 2b Clinical Trial of its REG1 Anticoagulation System 5
(Date:8/21/2014)... FL (PRWEB) August 21, 2014 The ... published today in The Journal of the American Medical ... more invasive cancers and reduces unnecessary recalls. Memorial Healthcare ... in the study. , “This study confirms what we ... invasive, harmful cancers we want to find and, at ...
(Date:8/21/2014)... 21, 2014 Xarelto lawsuit ( http://www.xareltolawsuitcenter.com/ ... to suffer uncontrollable internal bleeding and other serious injuries ... reports. According to court documents, a wrongful death lawsuit ... Easter District of New York by the family of ... event that was allegedly caused by Xarelto. Among other ...
(Date:8/21/2014)... UK (PRWEB) August 21, 2014 The ... USD 15.6 billion in 2014 and reach USD 18.3 ... the forecast period. The drivers of such growth include ... rising obese and diabetic population, and surging ageing population. ... of state-of-the-art wound care products. Region-wise, North America leads ...
(Date:8/21/2014)... 2014 The report "Industrial Flue ... Control System (FGD, DeNOx, Particulate Control, Mercury Control) ... Chemical & Others) - Global Trends & Forecasts ... flue gas treatment systems & services market with ... in terms of value. The industrial flue gas ...
(Date:8/21/2014)... NY (PRWEB) August 21, 2014 ... products manufactured by Boston Scientific has begun in ... first bellwether trial. The Rottenstein Law Group LLP, ... women with claims of harm stemming from the ... a claim for compensation for injuries suffered at ...
Breaking Medicine News(10 mins):Health News:Dr. Mary Hayes: Study Shows 3D Mammography Finds More Invasive Cancers While Reducing Unnecessary Recalls 2Health News:Xarelto Lawsuits Mount With New Filing in New York Federal Court, Bernstein Liebhard LLP Reports 2Health News:Xarelto Lawsuits Mount With New Filing in New York Federal Court, Bernstein Liebhard LLP Reports 3Health News:Xarelto Lawsuits Mount With New Filing in New York Federal Court, Bernstein Liebhard LLP Reports 4Health News:Global Wound Care Market to Post 3.2% CAGR Through 2019, Says MarketsandMarkets in Its New Report Published at MarketPublishers.com 2Health News:Global Wound Care Market to Post 3.2% CAGR Through 2019, Says MarketsandMarkets in Its New Report Published at MarketPublishers.com 3Health News:Industrial Flue Gas Treatment Systems Market Estimated to Worth $59, 546.7 Million by 2019 – Report by MarketsandMarkets 2Health News:Industrial Flue Gas Treatment Systems Market Estimated to Worth $59, 546.7 Million by 2019 – Report by MarketsandMarkets 3Health News:Industrial Flue Gas Treatment Systems Market Estimated to Worth $59, 546.7 Million by 2019 – Report by MarketsandMarkets 4Health News:Transvaginal Mesh Lawsuit News: Second Boston Scientific Mesh Bellwether Trial Begins, The Rottenstein Law Group LLP Reports 2
... found that there is an increase in number of children ... to tackle young criminals. According to the statistics the number ... offences due to alcohol increased by more than 150 % ... and theft. But the figures of the number of juveniles ...
... of us, reading others body language comes easy and ... people with schizophrenia,// may have a difficulty and ... ,But people with schizophrenia, even those who have ... fluent in understanding body language, according to a University ...
... are participating in the anti-reservation protest have stated that ... Government rolls back plans for reservation of seats in ... 300 have been provided with termination notices. ... government hospitals entered the eighth day Friday, students from ...
... Meeting of the American Society of Hypertension in New ... sexual dysfunction// (FSD) and high blood pressure. According to ... increased hypertension and increased age suffer from FSD. Female ... in sexual desire, persistent or recurring decrease in sexual ...
... being subjected to unnecessary stress as doctor’s order unwanted ... medical tests put a huge strain on the U.S. ... year. The study, conducted by researchers at the Georgetown ... published in the June issue of the American Journal ...
... from Copenhagen, the Danish authorities on Thursday have reported the ... // ,The Danish Veterinary and Food Administration ... a private farm near the city of Kerteminde in the ... hundred chickens, ducks and geese on the farm have been ...
Cached Medicine News:Health News:Schizophrenia impairs body language comprehension 2Health News:Schizophrenia impairs body language comprehension 3Health News:Doctors Urge Government To Roll Back Quotas 2Health News:Link Established Between FSD and High Blood Pressure 2Health News:U.S. Doctors Order Unwanted Medical Tests 2Health News:U.S. Doctors Order Unwanted Medical Tests 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: